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At odd with traditional views, effective sub-thalamic nucleus (STN) deep brain stimulation (DBS), in Parkinson’s disease (PD)
patients, may increase the discharge rate of the substantia nigra pars reticulata and the internal globus pallidus (GPi), in
combination with increased cyclic guanosine monophosphate (cGMP) levels. How these changes affect the basal ganglia (BG)
output to the motor thalamus, the crucial structure conveying motor information to cortex, is critical. Here, we determined the
extracellular GABA concentration in the ventral anterior nucleus (VA) during the ﬁrst delivery of STN-DBS (n¼10) or following
levodopa (LD) (n¼8). Both DBS and subdyskinetic LD reversibly reduced ( 30%) VA GABA levels. A signiﬁcant correlation
occurred between clinical score and GABA concentration. By contrast, only STN-DBS increased GPi cGMP levels. Hence, STN-
ON and MED-ON involve partially different action mechanisms but share a commontarget in the VA. These ﬁndings suggest that
the standard BG circuitry, in PD, needs revision as relief from akinesia may take place, during DBS, even in absence of reduced
GPiexcitability.However,clinicalameliorationrequiresfastchangeofthalamicGABA,conﬁrming,inlinewiththeoldmodel,that
VA is the core player in determining thalamo-cortical transmission.
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The classical basal ganglia (BG) model
1,2 postulated that, in
Parkinson’s disease (PD) akinesia results from a functional
imbalance between indirect and direct pathways. An over-
activity of the sub-thalamic nucleus (STN) and the internal
segment of the globus pallidus (GPi) was supposed to have a
key role in determining the OFF state. As similar beneﬁts
were obtained by STN deep brain stimulation (DBS) or
STN lesion, it was suggested that STN-DBS represented a
sort of functional ablation (‘the suppression hypothesis’, see
Filali et al.
3).
Some experimental studies using the 6-hydroxydopamine
(6-OHDA) rodent’s model corroborated those assumptions
(Benazzouz et al.
4; Windels et al.,
5,6 but consider Shi et al.
7).
Alternatively, the efﬁcacious STN-DBS, when delivered in
PD patients and non-human primates, increased—and not
decreased—GPi and substantia nigra pars reticulata (SNr)
discharge rate while modulating their pattern of activity; during
STN-DBSGPineuronalactivitywasindeedmoreregular,time-
locked to the stimulus pulse, and had less bursting activity.
8–10
When inhibition was found,
11 it derived from short micro-
stimulation periods, presumably conﬁned to the cell bodies.
Moreover, ﬁrst by disease modeling,
12 and later by
extracellular recordings during STN-DBS in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated primates,
those unexpected changes in GPi were found to be
associated with a modiﬁcation in the pattern of neuronal
activity in the pallidal (ventralis anterior, ventral anterior
nucleus (VA), as in the terminology of Hassler et al.
13) and
cerebellar (VL) receiving areas of the motor thalamus. The
resulting neuronal activity in both the thalamic regions
became increasingly periodic and regular, with a shift in
oscillatory activity from low to high frequencies.
14 Therefore,
all these data indicate that some premises of the standard
model,ifcenteredontheputativehyperactivityofspeciﬁc‘pre-
thalamic’ pathways, should be wrong, whereas not enough
attentionwas,sofar,dedicatedtothebiochemicalcounterpart
of those electrophysiological evidence.
Here, our aim was to identify any clinically related
biochemical change in GABA content occurring in the VA.
In addition, we asked whether different acute treatments,
namely levodopa (LD) or DBS, causing similar therapeutic
effects, also share biochemical parameters in the VA as a
possible ‘common transducer of efﬁcacy’.
In support of a common pathway, the maximal clinical
improvement by STN-DBS in the early postoperative stage
usually does not exceed that obtained with LD.
15,16 There
is also evidence against a common pathway; for example,
the different impact on OFF dystonia. Further, LD-mediated
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may differ strongly,
17,18 suggesting that incomplete mechan-
isms overlap.
Here, we took advantage of the ‘multi-target DBS strategy’,
where several PD patients were included to the bilateral
implantation of both STN and GPi;
16,19–21 this allowed to
collect – and correlate with clinical scores – microdialysis data
from the GPi and VA of the same patients (Figure 1). In
particular, we studied whether clinically effective STN-DBS
(185Hz) or intra-operative LD administration (at a sub-
dyskinetic dose) inﬂuenced GABA levels in the VA. In
addition, as our previous investigations had shown that
STN-DBS induced a large increase of cyclic guanosine
monophosphate (cGMP) concentration in the GPi, we
evaluated to what extent LD did replicate that ﬁnding, which
in turn would establish whether the nucleotide alteration is a
critical, and clinically related, feature, shared by both
therapeutic approaches.
The present work did not explore all the putative targets of
STN-DBS and LD; however, our data emphasize that, while
there may be some differences between LD and DBS
mechanisms, as indicated by the DBS-mediated increase
of GPi cGMP (in contrast with LD), the reduced GABA
availability inside the VA, seen with both LD and DBS, may
represent one critical index of any effective therapy for
PD rigidity and akinesia.
Results
Effects of STN-DBS
Thalamic GABA changes. DBS produced a signiﬁcant
decrease in GABA content during stimulation (Table 1 and
Figure 2; average 31.1%; ANOVA main effect df¼2/18;
e¼0.784, df¼1.56/14.11; F¼11.83, P¼0.000523; 0.0016
Greenhause–Geisser correction). Post hoc Sheffe ´ test
showed the following: basal versus DBS P¼0.000783;
DBS versus recovery P¼0.00413. Friedman ANOVA
followed by Wilcoxon conﬁrmed these levels of signi-
ﬁcance. In two cases, DBS was kept at 0V for 20min and
no consistent change of GABA was detected (not shown).
Pallidal cGMP changes. DBS produced a clear-cut increase
of cGMP as already described (Table 1 and Figure 2;
average 606.2%; ANOVA main effect df¼2/18; e¼0.515,
df¼1.03/9.28; F¼20.56, P¼0.00002). Post hoc Sheffe ´
test showed: basal versus DBS P¼0.000047; DBS versus
recovery P¼0.000489. Friedman ANOVA followed by
Wilcoxon test conﬁrmed these signiﬁcances.
Clinical effect of DBS. There was a signiﬁcant change of
Uniﬁed Parkinson’s Disease Rating scale (UPDRS) score
during STN-DBS (Table 1 and Figure 1; n¼10; df¼17;
w
2¼143.12; P¼0.000001 Friedman ANOVA). Post hoc
Wilcoxon test showed a signiﬁcant UPDRS score
amelioration from the ﬁrst 10min of DBS in comparison
with all the basal scores. The score was signiﬁcantly lower
throughout DBS and during the ﬁrst 10min of recovery.
Correlations. Clinical score signiﬁcantly correlated with
cGMP increase (R Spearman:  0.73, Po0.05) and GABA
decrease (R: þ0.67, Po0.05). No signiﬁcant correlation
was observed between GABA and cGMP changes.
LD Effects
Thalamic GABA changes. LD produced a signiﬁcant
decrease of GABA content during 2h after LD admini-
stration (Table 2 and Figure 3; ANOVA main effect df¼2/10;
e¼0.687, df¼1.37/6.87; F¼35.57, P¼0.000028; 0.000387
Figure 1 Trajectories of the multi-electrode probes holders aimed at the
STN-VA. Each section shows representative diagrams of the multi-electrode holder
(top) used and, at the bottom, two different partially superimposed sections of atlas
(notethehandleaﬁngthesuperiorsection).Thebottompanelshowsacoronalatlas
section at 1.5mm posterior to the inter-commissural midline (Fp 1.5, STN target)
and at 4mm anterior to the inter-commissural midline (Fa 4.0 VA target). To reach
the STN passing through the VA, the central electrode of the multi-electrode holder
(upperpart)wasaimedat atargetat8.5mmoflaterality, 4mmwithrespectto the
AC–PC plane, and at the mid-point of the AC–PC line. The trajectory had an angle
of 701–751 in the sagittal plane and of 851–901 in the coronal plane. The more
lateral electrode of the multi-electrode holder was at 3.5mm of laterality from the
central one. This laterality allowed to reach a target at 12.0mm of laterality from the
midline,which is the usuallocation of the STNtarget. On the contrary, the trajectory
of electrode-B was 1.5mm more medial than the central one and 2mm more
anterior. The probe membrane (4mm length) was positioned between 11.0 and
7.0mm above the target (þ7t oþ3mm above the inter-commissural plane),
along the trajectory of electrode-B. Given the angle in the sagittal planes (701–751),
the trajectory had a laterality of 7.0mm and, at the level of þ7t oþ3mm above
the inter-commissural plane, its anterior–posterior position was between þ6 and
þ4mmwith respectto themidpointof theinter-commissuralline, corresponding to
the center of the VA
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Cell Death and DiseaseGreenhause–Geisser correction). Post hoc Sheffe ´ test
showed the following: basal versus ﬁrst LD hour
P¼0.000034; basal and ﬁrst LD hour versus 2nd LD hour,
NS. Friedman ANOVA followed by Wilcoxon test conﬁrmed
these signiﬁcances. The average GABA decrease was 25%
in the ﬁrst hour and 15.9% in the second hour. LD effect was
signiﬁcant from the third fraction (from 20 to 30min) up to the
third fraction of the second hour (Table 2 and Figure 3).
Pallidal cGMP changes. LD did not produce a signiﬁcant
change (Figure 3), although the mean cGMP concentration
decreased from 1.89fmol/50ml in the basal fractions
to 1.65fmol/50ml in the fractions from the ﬁrst hour, and to
1.64fmol/50ml during the second hour. Friedman ANOVA
followed by Wilcoxon test conﬁrmed this lack of signiﬁcance.
However, examination of the individual patients’ data showed
a trend for no change in subjects presenting with low cGMP
basal values (o1.5fmol close to the detection limit), but a
clear decrease (approximately 50%) after LD administration
in subjects presenting with higher basal values (43.0fmol,
patient-2 and 6; highlighted in Table 2). This suggested
a ‘ﬂoor’ effect in subjects with low basal values.
Clinical effect of LD. Friedman ANOVA showed a signiﬁcant
change of UPDRS score after LD administration (n¼6;
df¼17; w
2¼83.13; P¼0.000001). Post hoc Wilcoxon test
showed a signiﬁcant UPDRS score amelioration 30min after
LD administration in comparison with all the basal scores.
The score was signiﬁcantly lower up to 80min after LD
administration.
Correlations. A signiﬁcant correlation was observed between
GABA and cGMP changes (Pearson correlation r¼0.97,
t¼8.01, P¼0.0013), and between GABA and clinical score.
A closer look, case by case, at the GABA decrease and the
UPDRS scores in both sub-groups (LD, alias melevodopa,
and DBS; Figure 4) allows to recognize the homogeneity of
the response following the drug challenge (Figure 4, left plot),
Table 1 Microdialysis values and clinical scores before, during, and after STN-DBS
Basal STN-DBS Recovery
cGMP-GPi
Patient Mean Mean Mean
1 2.4 2.2 1.9 2.4 2.1 2.2 2.2 4.4 9.7 24.5 22.1 29.7 30.1 20.1 28.5 2.4 1.3 1.1 2.1 2.3 6.3
2 1.7 1.3 1.7 1.5 1.4 1.5 1.5 2.7 2.3 2.5 3.2 3.1 3.4 2.9 3.9 2.1 1.5 1.4 1.2 1.3 1.9
3 2.5 1.9 2.4 1.6 2.0 2.1 2.1 3.0 2.7 2.3 2.3 2.5 2.9 2.6 3.2 2.0 1.5 1.1 2.1 2.3 2.0
4 1.0 1.5 1.1 1.0 1.0 1.1 1.1 2.5 9.4 10.7 12.6 10.9 11.2 9.6 12.1 1.9 1.1 1.4 1.1 1.4 3.2
5 1.3 1.1 1.7 1.3 1.2 1.3 1.3 4.4 8.2 16.4 15.5 17.2 16.1 13.0 15.2 2.2 1.2 1.1 1.3 1.4 3.7
6 1.9 2.1 2.8 2.3 2.4 2.3 2.3 3.1 2.8 3.5 5.9 6.4 5.1 4.5 13.4 2.7 1.8 1.5 2.2 1.5 3.9
7
a 1.0 1.1 1.5 1.0 1.0 1.1 1.1 3.5 4.9 12.3 13.6 13.1 13.0 10.1 5.6 2.3 1.2 1.3 1.1 1.2 2.1
8 1.3 1.0 1.3 1.2 1.4 1.2 1.2 1.4 3.7 10.0 10.6 9.2 11.0 7.7 4.1 2.0 1.4 1.2 1.3 1.1 1.9
9 1.7 1.3 1.4 1.5 1.7 1.5 1.5 2.1 11.9 17.9 17.8 17.9 16.9 14.1 8.2 2.3 1.2 1.8 1.1 1.7 2.7
10
a 1.7 1.5 1.7 1.8 1.7 1.7 1.7 4.4 8.2 14.2 15.5 15.3 16.1 12.3 13.1 3.2 1.2 1.5 1.3 1.4 3.6
Mean 1.7 1.5 1.8 1.6 1.6 1.6 1.6 3.2 6.4 11.4 11.9 12.5 12.6 9.7 10.7 2.3 1.3 1.3 1.5 1.6 3.1
S.D. 0.5 0.4 0.5 0.5 0.5 0.4 0.5 1.0 3.5 7.3 6.4 8.1 8.1 5.7 7.7 0.4 0.2 0.2 0.5 0.4 1.6
GABA-VA
1 5.1 4.7 4.5 4.8 5.3 4.9 4.9 3.2 3.1 3.3 3.5 3.4 3.1 3.3 3.8 4.0 4.0 4.2 4.5 4.5 4.2
2 4.0 3.9 3.7 4.3 4.1 4.0 4.0 3.0 4.0 3.5 3.9 3.2 3.0 3.4 3.0 3.3 4.1 5.4 6.3 5.0 4.5
3 4.2 4.1 4.3 4.7 4.5 4.4 4.4 3.9 4.1 3.9 4.1 3.8 3.8 3.9 3.4 4.0 5.8 6.2 5.3 5.7 5.1
4 4.3 4.0 4.5 4.9 4.3 4.4 4.4 3.9 3.7 4.0 4.0 3.8 3.9 3.9 3.7 3.7 3.9 3.5 3.4 3.7 3.7
5 4.9 4.3 4.1 4.5 4.7 4.5 4.5 4.1 4.2 3.9 3.8 4.1 4.1 4.0 1.5 2.3 3.0 3.5 4.0 3.4 3.0
6 5.1 5.6 5.4 5.3 5.5 5.4 5.4 3.5 2.1 2.0 2.0 2.1 1.7 2.2 5.0 5.0 5.5 5.3 6.3 6.0 5.5
7
a 4.0 4.1 4.5 4.1 4.8 4.3 4.3 2.7 2.7 2.8 2.7 2.7 3.2 2.8 3.8 4.1 4.5 4.3 4.2 4.5 4.2
8 4.9 5.1 5.3 4.9 4.7 5.0 5.0 2.9 2.6 2.4 2.3 2.3 2.3 2.5 3.5 3.2 4.1 4.5 4.8 5.0 4.2
9 4.1 3.7 3.7 4.1 3.6 3.8 3.8 3.1 2.7 1.5 1.7 1.2 1.4 1.9 2.0 2.6 3.2 3.1 3.9 4.1 3.2
10
a 4.5 4.5 4.0 4.0 4.4 4.3 4.3 3.9 3.0 2.6 2.4 2.4 2.4 2.8 4.7 5.0 5.1 5.3 4.9 4.7 5.0
Mean 4.5 4.4 4.4 4.6 4.6 4.5 4.5 3.4 3.2 3.0 3.0 2.9 2.9 3.1 3.4 3.7 4.3 4.5 4.8 4.7 4.2
S.D. 0.5 0.6 0.6 0.4 0.6 0.5 0.5 0.5 0.7 0.9 0.9 0.9 0.9 0.8 1.1 0.9 0.9 1.0 1.0 0.8 0.9
UPDRS
1 9.0 8.0 10.0 9.0 10.0 9.0 9.2 8.0 5.0 4.0 4.0 4.0 4.0 4.8 5.0 8.0 9.0 10.0 10.0 10.0 8.7
2 7.0 8.0 7.0 7.0 8.0 7.0 7.3 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 8.0 8.0 8.0 8.0 9.0 7.8
3 8.0 7.0 7.0 8.0 8.0 8.0 7.7 7.0 6.0 6.0 6.0 6.0 6.0 6.2 6.0 8.0 7.0 8.0 8.0 8.0 7.5
4 9.0 10.0 10.0 9.0 11.0 10.0 9.8 9.0 7.0 7.0 6.0 6.0 6.0 6.8 6.0 9.0 9.0 10.0 11.0 11.0 9.3
5 8.0 7.0 8.0 8.0 8.0 8.0 7.8 6.0 5.0 4.0 4.0 4.0 4.0 4.5 6.0 8.0 8.0 7.0 8.0 9.0 7.7
6 9.0 9.0 10.0 10.0 9.0 9.0 9.3 9.0 8.0 8.0 8.0 8.0 8.0 8.2 8.0 9.0 9.0 10.0 11.0 10.0 9.5
7
a 9.0 8.0 8.0 9.0 9.0 9.0 8.7 7.0 5.0 5.5 4.5 4.5 5.0 4.8 6.0 8.0 8.0 9.0 8.0 9.0 8.0
8 7.0 8.0 7.0 8.0 8.0 8.0 7.7 5.0 5.0 5.0 5.0 4.0 4.0 4.7 5.0 8.0 7.0 8.0 8.0 8.0 7.3
9 8.0 7.0 8.0 7.0 8.0 8.0 7.7 6.0 5.0 4.5 5.0 4.5 4.5 4.5 6.0 8.0 8.0 7.0 8.0 9.0 7.7
10
a 9.0 9.0 8.0 9.0 9.0 8.8 8.8 6.0 5.0 4.5 4.0 4.0 4.5 4.3 6.0 8.0 8.0 9.0 8.0 9.0 8.0
Mean 8.3 8.1 8.3 8.4 8.8 8.5 8.4 6.9 5.7 5.3 5.0 5.0 5.0 5.5 6.0 8.2 8.1 8.6 8.8 9.2 8.2
S.D. 0.8 1.0 1.3 1.0 1.0 0.8 1.0 1.4 1.1 1.4 1.5 1.4 1.4 1.4 0.8 0.4 0.7 1.2 1.3 0.9 0.9
aPatients undergone an LD challenge after delivery of STN-DBS
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Cell Death and Diseasewhereas the DBS response features a much larger deviation
(Figure 4, right plot). In many, but not all, patients the degree
of clinical improvement tends to correlate with the change
of GABA concentrations (see, for instance, cases 2–4 of the
STIM group). Of course, the limited amount of cases
discouraged further interpretations.
Finally, in two cases it was possible, given the patients’
cooperation, to perform an LD challenge after the delivery of
STN-DBSinthesamesurgerysession(assumingthatmostof
the DBS-mediated effects were over after an 80-min STIM
cessation).ConsidertheexampleinFigure5,whichhighlights
thesimilareffectsonGABAlevelsof185-HzDBSand100-mg
LD on the very same PD patient.
Discussion
GABA decrease in the VA thalamus, during effective
STN-DBS or following LD administration, appears consistent
with some aspects of the established model of BG function.
1,2
Reduced GABA levels within the motor thalamus should
dis-inhibit VA ﬁring activity, with a profound impact on its
patterning; reduced bursting and/or suppressed oscillatory
activity are the most likely results, as inferred.
22 The precise
ﬁring properties of the human VA/VL during effective
STN-DBS are unknown, but previous studies in NHP may
help the interpretation.
Extracellular recordings in MPTP-intoxicated primates
documented, during STN-DBS, the relevant modiﬁcation in
the pattern of neuronal activity in the pallidal and cerebellar
Table 2 Microdialysis values and clinical scores before and during the ﬁrst and second hour after LD intake
Basal First hour after LD Second hour after LD
cGMP-GPi
Patient Mean Mean Mean
1 1.3 1.1 1.3 1.2 1.4 1.3 1.3 1.4 1.4 1.2 1.3 1.4 1.3 1.3 1.2 1.3 1.4 1.2 1.1 1.3 1.3
2
a 3.2 3.0 3.0 3.1 3.1 3.1 3.1 3.0 2.9 2.4 2.1 1.9 1.9 2.4 2.1 2.0 1.9 2.3 2.7 3.0 2.3
3 1.3 1.3 1.7 1.1 1.5 1.4 1.4 1.3 1.5 1.5 1.3 1.5 1.6 1.5 1.4 1.3 1.3 1.7 1.2 1.3 1.4
4 1.2 1.4 1.2 1.3 1.2 1.3 1.3 1.4 1.2 1.4 1.3 1.2 1.3 1.3 1.2 1.3 1.3 1.2 1.2 1.3 1.3
5 1.5 1.2 1.3 1.3 1.2 1.3 1.3 1.4 1.2 1.3 1.2 1.2 1.3 1.3 1.3 1.1 1.3 1.4 1.4 1.5 1.3
6
a 3.0 3.1 3.2 3.1 3.0 3.1 3.1 2.9 3.0 2.4 2.1 1.4 1.3 2.2 1.9 2.0 2.1 2.3 2.7 3.0 2.3
Mean 1.9 1.9 2.0 1.9 1.9 1.9 1.9 1.9 1.9 1.7 1.6 1.4 1.5 1.7 1.5 1.5 1.6 1.7 1.7 1.9 1.6
S.D. 0.9 0.9 0.9 1.0 0.9 0.9 0.9 0.8 0.8 0.6 0.4 0.3 0.3 0.5 0.4 0.4 0.4 0.5 0.8 0.9 0.5
GABA-VA
1 4.9 4.3 4.0 4.3 4.0 4.3 4.3 4.5 4.0 3.2 3.0 2.9 2.7 3.4 3.0 3.2 3.2 3.7 4.0 4.0 3.5
2 4.1 4.3 4.9 4.3 4.5 4.4 4.4 4.2 4.0 3.2 3.0 2.5 2.3 3.2 2.4 2.3 3.0 3.5 4.0 4.0 3.2
3 4.2 4.5 4.3 3.9 4.1 4.2 4.2 4.1 4.0 3.2 3.0 2.8 2.8 3.3 2.8 3.0 3.3 4.2 4.5 4.2 3.7
4 4.2 4.3 4.3 4.7 4.3 4.4 4.4 4.2 4.1 3.0 3.0 3.1 2.7 3.4 2.9 3.3 4.0 4.0 4.2 4.5 3.8
5 4.6 4.7 4.9 4.7 4.6 4.7 4.7 4.0 3.7 3.3 3.5 3.2 3.1 3.5 3.3 4.2 5.1 4.6 4.7 5.0 4.5
6 4.9 4.5 4.2 4.3 4.3 4.4 4.4 4.2 4.0 3.0 3.2 2.2 2.0 3.1 2.3 2.3 3.2 3.6 4.1 4.2 3.3
Mean 4.5 4.4 4.4 4.4 4.3 4.4 4.4 4.2 4.0 3.2 3.1 2.8 2.6 3.3 2.8 3.1 3.6 3.9 4.3 4.3 3.7
S.D. 0.4 0.2 0.4 0.3 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.4 0.4 0.2 0.4 0.7 0.8 0.4 0.3 0.4 0.5
UPDRS
1 10.0 8.0 8.0 10.0 9.0 9.0 9.0 10.0 8.0 6.0 5.0 5.0 5.0 6.5 5.0 5.0 7.0 8.0 10.0 9.0 7.3
2 7.0 8.0 7.0 7.0 8.0 8.0 7.5 8.0 7.0 5.0 4.0 4.0 4.0 5.3 5.0 5.0 7.0 8.0 9.0 8.0 7.0
3 7.0 8.0 8.0 7.0 8.0 8.0 7.7 8.0 8.0 5.0 5.0 4.0 4.0 5.7 4.0 5.0 5.0 8.0 8.0 8.0 6.3
4 10.0 9.0 11.0 10.0 9.0 10.0 9.8 9.0 9.0 7.0 6.0 6.0 5.0 7.0 6.0 9.0 10.0 9.0 9.0 11.0 9.0
5 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 6.0 6.0 5.0 5.0 6.3 5.0 7.0 10.0 8.0 8.0 8.0 7.7
6 7.0 8.0 7.0 7.0 8.0 8.0 7.5 8.0 7.0 5.0 4.0 4.0 4.0 5.3 4.0 4.0 6.0 8.0 8.0 8.0 6.3
Mean 8.2 8.2 8.2 8.2 8.3 8.5 8.3 8.5 7.8 5.7 5.0 4.7 4.5 6.0 4.8 5.8 7.5 8.2 8.7 8.7 7.3
S.D. 1.5 0.4 1.5 1.5 0.5 0.8 1.0 0.8 0.8 0.8 0.9 0.8 0.5 0.8 0.8 1.8 2.1 0.4 0.8 1.2 1.2
aPatients showing higher basal cGMP levels (see text)
Figure2 MicrodialysisdatafromtheGPiandVA,andclinicalevaluationbefore,
during, and after STN-DBS. Clinically effective STN-DBS caused a clear
augmentation of cGMP in the GPi and a statistical signiﬁcant GABA reduction in
theVA (see sectionResults). The clinicalscores at the bottom(dottedline, selected
items 22, 24, and 25 from UPDRS III) validate the effectiveness of the STN-DBS.
The data are expressed as the mean±S.D.
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Cell Death and Disease(VL) receiving areas of the motor thalamus. Both regions
showed a more periodic and regular pattern, and a shift in
oscillatory activity from low to high frequencies.
14
Further, the Rubin and Terman
12 model emphasized that a
beneﬁcial STN-DBS induces clustered ﬁring patterns in GPi,
whose clear consequence is a regularization of VA discharge
(more tonic, no pausing). As pointed out by Guo et al.,
STN-DBS altered Parkinsonian GPi activity in a way that may
improve thalamo-cortical relay ﬁdelity.
12,22 Accordingly, the
reduced GABA levels that we observed would impede
prolonged post-spiking after hyper-polarization, and favors a
more regular pattern of neuronal activity.
As an additional conﬁrmation of the clinical relevance of the
reduced levels of GABA in the VA, consider the relationship
between the degree of GABA decline under LD and the
degree of LD-mediated clinical beneﬁt (Figure 4). This is even
more reliable when patients under evaluation are, as here,
those in whom pharmacological sensitivity to LD was
consistently assessed during the pre-surgery phase.
Thalamic VA/VL nuclei form a crucial link between BG
outputs and speciﬁc cortical areas.
23 It is reasonable to
speculate that, once VA–VL is modulated by STN-DBS (as a
consequence of reduced GABA release), immediate changes
in thalamo-cortical transmission occur. PET studies reported
a re-activation of fronto-temporo-parietal cortex at rest after
effective STN-DBS (Hilker et al.,
24 but see Hershey et al.,
25).
Even when high-frequency STN-DBS decreased rCBF in the
motor cortex at rest – implying a reduction of abnormal over-
activity in the motor system – this allowed selective cortical
reactivation during movement.
26 Further, increased, move-
ment-related, activity in MC followed efﬁcacious pallidal
DBS
27 and STN-DBS in primates (J Vitek, unpublished).
It is difﬁcult to match the GABA decrease in the VA with the
increasedcGMPreportedintheGPi(orSNr)duringSTN-DBS
(this paper and Galati et al.
9, Stefani et al.
20), indicative of
increased GPi ﬁring. As a matter of fact, the NOS/guanylate
cyclase (sGC) pathway is mainly activated by glutamatergic
excitatory transmission and extracellular cGMP, which is
monitored by intra-cerebral microdialysis, reﬂects the in vivo
functional state of this neurochemical pathway (for a review,
see Pepicelli et al.
28). Thus, the augmentation of cGMP in the
GPi is a clear, although indirect, measure of pallidal neuron
excitation driven by DBS-mediated glutamate release.
In principle, these ﬁndings do not ﬁt with the early
BG model, at least when suggesting that modulation of the
hyper-excitability of the ‘indirect pathways’ is critical to rescue
from akinesia.
Figure 3 Microdialysis data from the GPi and VA, and clinical evaluation before
and during LD (100mg melevodopa) administration. In agreement with STN-DBS
treatment,LDcauseastatisticallysigniﬁcantGABAreductionintheVA(upperpart).
LD produced a signiﬁcant GABA decrease from the third fraction up to 50min.
On the contrary, LD induced a negligible effect on GPi cGMP; a decrease of cGMP
levels,ifany,wasobservedintwopatients(highlightedpatientsinTable2,no.2and
no. 6; see section Results). The data are expressed as the mean±S.D. Melevodopa
(LDmethylester)isasolubleformofLD,
47notcurrentlyinuseintheUnitedStates, but
routinely used in Italy(Sirio, by Chiesi Pharmaceuticals, Parma, Italy) in order to obtain
a relatively fast LD-like response (plasma peak at 20–50min)
Figure 4 Correlation between biochemical change of VA GABA and clinical
score.Theplot showsindetail,caseby case,theGABAandUPDRSdeclineduring
the drug response (left plot) and the DBS effect (right plot). The data are presented
as % decrease. The biochemical data are the average of the last two fractions
before the start of each challenge. The clinical score represents the average of the
last twofractions of the ﬁrst hour following LD challengeor DBS switch-on. Note, on
the left, the relative homogeneity of the response (comprised between 32 and 53%)
Figure 5 Microdialysis data showing changes of GABA in the VA and of
clinical scores before and during STN-DBS and, subsequently, following LD
(100mg melevodopa) administration. A similar reduction of GABA is produced by
both treatments. The protocol was slightly shortened with respect to routine-1
(i.e. 30min¼3 samples for DBS response) and was stopped before complete
recovery of GABA levels in order to reduce surgery time
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Cell Death and DiseaseHowever, the cGMP data are not artifactual (and acquired
from severe PD patients!); in addition, cGMP correlated
with clinical beneﬁts, whereas it was null if DBS was fake
(0V; Figure 1 in Stefani et al.
20). Besides, distribution studies
have shown that nNOS and soluble sGC (both a-1 and b-1
subunits) are present at relatively high levels in the GPi of the
human brain.
29,30 These studies, although not determining a
precise cellular localization indeed provide the biochemical
basis for nitric oxide/cGMP production in this brain region.
Furthermore, the large DBS-mediated increase of GPi
cGMP matches with an abundant literature. Strong support
for an ‘increased’ GPi functional activity was raised by PET
studies in PD patients,
25 electrophysiological studies in
MPTP-treated primates,
8 increased cytochrome oxidase
subunit-1 (COI) mRNA expression,
31 and modeling studies
supporting axonal activation of the STN neurons during
STN-DBS.
32
So, the issue is not whether an increased ﬁring in the
GPi/SNr during STN-DBS is observed (several demonstra-
tions are available), rather to what extent this correlates with
the decreased thalamic GABA.
One possibility is that the STN-DBS-mediated increase
of GPi neuronal activity leads to the reduction of thalamic
GABA release owing to the frequency-dependent activation
of inhibitory GABAB auto-receptors on VA GABAergic
terminals, as it happens in the hippocampus during the
induction of long-term potentiation.
33
In the anterior thalamus, complex synaptic arrangements,
including triads of three GABAergic synapses (pallidal and
reticular ﬁbers with local inter-neurons or projection cell
dendrites) and serial synapses with local GABAergic inter-
neuronsthatinturnestablishsynapticcontactswithprojection
cell dendrites, compose up to 50% of synaptic contacts.
34
Therefore, it could be hypothesized that DBS-driven
GPi activity would enhance GABA release from GPi ﬁbers
onto VA–VL GABAergic inter-neurons, which in turn would
decrease synaptic inhibition on thalamic glutamatergic neu-
rons, ﬁnally re-activating the thalamo-cortical pathway. If this
were the case, the small, though signiﬁcant, decrease of
thalamic GABA levels we observed could underestimate a
more marked reduction in release from thalamic GABAergic
inter-neurons.
Another possible explanationis thatthe electric ﬁeld around
the STN-DBS electrode inhibits large (1.5–5.0mm diameter)
GPi ﬁbers directed to the thalamus and passing along the
dorsal border of the STN, while simultaneously exciting thin
STN-GPi/SNr ﬁbers.
35
Third, an augmentation of cGMP levels may reﬂect
regularization of neuronal activity as well as an increase in
the mean discharge rate, and it may be the regularization that
is more important in modifying the GABA levels in the
thalamus. As noted previously, STN-DBS act as a modulator
of endogenous oscillations.
22 One model predicts that even
during an (apparent) increase of GPi discharge, the more
tonic ﬁring pattern may impede irregular GABA release
(propelled by spike trains) on target thalamo-cortical cells,
restoring their responsiveness to sensory inputs.
12
Alternatively, the two examined effects of DBS (increased
cGMP in GPi and lower GABA in VA) might not be necessarily
linked. Actually, STN-DBS reverberates on multiple
sites, including a ventral tegmental area and pedunculopon-
tine nucleus extended area,
36 which in turn affects
the ascending pathways toward the thalamus. In other
words, the proteiform response to DBS on distant structures
might overcome the strict boundaries of the direct/indirect
pathway scheme.
In line with DBS-mediated mechanisms, LD promoted a
similar decrease of GABA levels in the VA, together with a
signiﬁcant clinical improvement. To note, the LD-mediated
decline of GABA was clearly more homogeneous than
the DBS response (see Figure 4). In contrast with DBS, the
LD-induced decline of GABA in the VA coincides with a
reduction of GPi activity,
3,37–39 but with a negligible effect on
GPi cGMP levels. In our experience, the apomorphine
response in the GPi of human PD patients was characterized
by a dose-dependent fast inhibition and showed partial
desensitization.
40
However, two subjects with higher basal levels of cGMP
showed a clear decrease after LD administration, suggesting
that LD might reduce GPi cGMP, an effect hard to detect if
basal cGMP levels are close to the detection limit (as in the
other four patients).
On the other hand, lack of cGMP change during LD
challenge may imply functional de-rearrangements of the
dopamine–cGMP interplay in advanced PD patients.
It has been reported that unilateral lesions of the nigro-
striatal pathway with 6-OHDA in rats resulted in a signiﬁcant
decrease of cGMP levels in the ipsilateral caudate-putamen
(CP) and GP.
41,42 Interestingly, in 6-OHDA-lesioned eukinetic
ratsadministrationofLDfailed to affectthecGMP levelsinthe
ipsilateral CP and GP, whereas it was able to decrease those
levels in the same regions on the non-lesioned contralateral
side; on the contrary, LD lowered cGMP levels in both
hemispheres in 6-OHDA-lesioned rats at the peak of LD-
induced dyskinesia.
42 These results highlight that the cGMP
response to LD in the BG could be different under dyskinetic
and non-diskynetic conditions, and might explain the lack
of LD-induced changes of cGMP in the GPi, as LD was
administered to patients at a sub-dyskinetic dose.
Functional implications. The core ﬁnding of this
investigation is the consistent and clinically related GABA
decline in the motor thalamus, which may associate (during
DBS) or may not associate (under LD) with simultaneous
changes of GPi cGMP. Hence, the clinically relevant
modulation of GABA in the VA occurs despite or besides
ongoing changes of pallidal discharge. Parsimonious
implications are that, during LD-mediated clinical amelio-
ration, pathways other than the pallido-thalamic, but still
affecting the VA, indeed contribute to the rebalancing of the
thalamo-cortical output.
That said, the common effect on VA GABA levels, shared
by both treatments, indicates that this reduction reﬂects some
degree of mechanistic similarity underlying the clinical effects
of STN-DBS and LD.
Few centers still use unilateral pallidotomy as a competitive
surgical approach
43 (of course, in advanced PD patients
affected by disabling dyskinesias and reluctant to undergo
bilateral DBS). Pallidotomy would suppress ipsilateral GABA
transmission in the VA/VL. Our present data lend support to a
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Cell Death and Diseaseputative re-evaluation of selective ablations (to interfere with
endogenous release of GABA in VA) or, speculatively,
to the implementation of devices aimed at rebalancing
intra-thalamic GABA levels.
The dichotomy between the STN- and LD-mediated effects
on the cGMP levels in GPi is not, per se, surprising if we take
into account their different electrophysiological effects. In
contrast with DBS, which may excite and/or cluster neuronal
activity, exogenous LD has a strong inhibitory inﬂuence on the
neuronal activity of GPi.
38 An almost complete suppression of
GPi discharge associates with LD-induced dyskinesia!
38,44
In conclusion, a number of investigations from multiple
disciplines support the hypothesis that stimulation-induced
modulation of pathological network activity represents
the most likely mechanism of DBS.
45 Recent contribution
(by using an optogenic approach) suggested that high-
frequency STN stimulation, in 6-OHDA rodents, promotes
mostly a direct activation of cortical axons to STN.
46
Nevertheless, in agreement with recent conclusions of
Johnson et al.
27 (‘DBS improves Parkinsonian motor symptoms
by inducing global changes in ﬁring pattern and rate along the
pallido-thalamocortical sensorimotor circuit’), our results further
emphasize the motor thalamus as the critical station where
efﬁcacious re-modulation (electrical or pharmacological) of
pathological outputs promotes good therapeutic outcomes.
Materials and Methods
Patients. Sixteen advanced PD patients (mean age¼58.9±6.5 years; mean
UPDRS score in OFF¼46.7±9.1; mean disease duration¼11.4±3.7 years)
were included in the study according to previously reported selection criteria.
19,38,39
For epidemiological data, see Table 3. Response to STN-DBS was analyzed in 10
patients and response to L-DOPA was monitored in six patients. Actually, we
routinely used melevodopa (Sirio 100þ25), a soluble analog of LD/carbidopa,
introduced since early 2000s in clinical practice in Italy. Given its pharmacokinetic
proﬁle,
47melevodopaallowstoobtainaconsistentpeakresponsein20–50min,still
maintaining an adequate steady-state response, at least in the 2h examined here.
In order to avoid misunderstanding, LD is used throughout the entire paper.
The two groups did not manifest signiﬁcant differences in terms of disease
history, duration, or LD dosage.
In addition, two PD patients accepted to undergo, in sequence, both STN-DBS
and LD challenge, albeit with a shortened protocol.
Surgical and microdialysis technique. Permanent electrodes were
implanted in both the STN and the GPi, bilaterally, according to our previous
multi-target strategy.
48 For trajectory details, and implantation procedures, see our
previous works
19–21 and the legend in Figure 1.
Written, informed consent was obtained from each patient. The Local Ethics
Committee of the University of Tor Vergata approved the protocol and the consent
form describing the risks and potential beneﬁts of the study. The protocol included
the following step procedures: electrophysiological single-unit micro-recordings in
STN for proper identiﬁcation of the best trajectory for lead implantation; insertion
of the permanent DBS lead (Medtronic 3389) into the STN (ﬁnal coordinates¼
AC–PC/2, 11–12mm lateral to the midline, and 4–5mm below the AC–PC);
insertion of guide tubes into the VA and GPi for microdialysis (only at the end of the
microdialysis session the permanent electrode was positioned also in the GPi,
whose coordinates are as follows (for the lowest contact): 2–3mm anterior to the
AC–PC/2,19–22mmlateraltothemidlineofthethirdventricle,and6mmbelowthe
inter-commissural line;
16). To note, microdialysis onto human Parkinsonian brain
was pioneered by Ungerstedt,
49 extensively used by our group,
9,19–21 and recently
replicated by Kilpatrick et al.
50
As previously reported,
19 the microdialysis concentric probes had the following
features: external membrane diameter 0.6mm, external tube diameter 0.5mm,
membrane PES with 20-kDa molecular weight cutoff, 4-mm dialyzing zone for GPi
andVA(MetalantAB,Metalant,Sweden).Themicrodialysisprobeswereconnected
to a CMA100 microinjection pump (CMA Microdialysis, Stockholm, Sweden) set at
5ml/min. Perfusion was started immediately with a sterile PBS solution containing
(in g/l) NaCl (8), KCl (0.2), CaCl2 2H 2O (0.132), MgCl2 6H 2O (0.1), Na2HPO4
(1.15), KH2PO4 (0.2) (pH 7.4). The outlet of the probes was placed into plastic vials
situatedin a standﬁtted to a stereotaxicframe. Completesterility of all thematerials
used (probes connectors, tubing, vials, and solutions) was assured. Samples were
collected every 10min and immediately frozen. The amount of GABA in each
fraction was determined by HPLC analysis coupled to ﬂuorimetric detection. The
buffers and gradient program used were those reported by Fedele and Raiteri.
51
Homoserine was used as internal standard; the detection limit for GABA was
approximately100fmol/40ml. In order to ascertain that all theprobes used sampled
GABA with the same efﬁciency, at the end of the operation they were tested in vitro
using standard solutions to determine the relative recovery of GABA (no signiﬁcant
difference for in vitro recovery has been observed among the probes used for
differentpatients).Themeanbasalvaluesoftheaminoacidcollectedbyeachprobe
in any patient were calculated from the tenth fractions (all fractions before assumed
as under stabilization and, thus, discarded). cGMP concentration was determined
by radio-immunoassay (RIA) as already described.
20
Attheendofthestabilizationphase(90min),basalmicrodialysissamples(60ml,
10min each) and clinical data were collected for 60min (see Figures 2 and 3).
Afterwards, either STN-DBS was switched on for 60min (n¼10 patients; Table 1
and Figure 2; the stimulation parameters for bipolar STIM were approximately
185Hz, mean 2V (range 1.8–2.4), 60ms duration etc.) or melevodopa was
administered orally (100mg, n¼6 patients; Table 1 and Figure 3).
After a 60-min DBS, 60min of recovery were performed (Table 1). After LD
administration, dialysis continued for further 120min (two 60-min periods; Table 1).
All procedures were without additional risks for the patients, as the guide tubes
for micro-recordings were already placed in each target (STN and GPi). That said,
the microdialysis procedure per se indeed prolongs (an average of 3.5h) the entire
surgery section. This is why only in special occasions it was possible to obtain
microdialysis data under both clinical challenges, albeit with a shortened protocol
(DBS followed by LD, n¼2; see Figure 5), or it was possible to check the lack of
GABA title changes during a 0-V STN-DBS (n¼2, not shown).
Clinical changes were assessed using a subset of the items of UPDRS (rigidity
0–4, ﬁnger tapping 0–4, hand movement 0–4; total¼0 corresponds to ‘normal’,
12 maximumscore)byaneurologistblindedtothestimulusintensitybetween0and
3V or the time of LD administration.
Statistical analysis. Mean GABA and cGMP levels (expressed as pmol or
fmol/50ml, respectively) were compared by two-way ANOVA (ﬁrst main factor:
Table 3 Clinical characteristics of the 16 PD patients in the study
PD patient
Age
(years)
Disease
duration
(years)
L-DOPA
duration
(years)
L-DOPA
daily
dose (mg)
DBS
1 68 10 10 750
2 60 23 23 800
3 52 10 7 600
4 49 15 13 900
5 59 12 12 1000
6 56 13 12 800
7 63 10 10 1000
8 64 11 11 1300
DBS+L-DOPA
9 54 7 7 800
10 65 9 9 1100
L-DOPA
11 48 12 11 750
12 54 11 6 1200
13 62 10 8 750
14 69 10 9 1050
15 55 7 7 800
16 65 13 9 1000
17 58 9 7 750
18 60 12 8 1325
Mean (±) S.D. 58.9±6.1 11.3±3.5 9.9±3.8 925±210
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Cell Death and Diseasetreatment with three levels: basal, treatment (DBS, LD, or none), recovery; second
main factor: time with six levels) corrected by Greenhause–Gaisser correction and
followed by post hoc Sheffe ` test to assess the signiﬁcance of the differences
betweensinglefractions.AsimilarprocedurewasusedforLDadministrationexcept
the three levels of the ﬁrst main factor were basal, LD1 (0–60min after LD
administration), and LD2 (60–120min).
Given the possible non-normality of biochemical data, the results were also
conﬁrmedby non-parametric FriedmanANOVA followedby Wilcoxonpost-hoc test.
The clinical scores were compared using similar non-parametric methods.
Correlations were studied between the maximal changes in the GABA and cGMP
concentrations induced by DBS and LD (Pearson parametric correlations), and
clinicalscore(non-parametricSpearmancorrelations).Thechangeswereevaluated
asthemaximumchangeofeachoftheseparametersincomparisonwiththeirmean
basal score.
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